(Q40301795)

19 September 2017

title

Reference profiling of the genomic response induced by an antimicrotubule agent, TZT-1027 (Soblidotin), in vitro (English)

1 reference

19 September 2017

T Shimoyama

1

1 reference

19 September 2017

T Hamano

2

1 reference

19 September 2017

T Natsume

3

1 reference

19 September 2017

F Koizumi

4

1 reference

19 September 2017

K Kiura

5

1 reference

19 September 2017

M Tanimoto

6

1 reference

19 September 2017

K Nishio

7

1 reference

19 September 2017

publication date

21 March 2006

1 reference

The Pharmacogenomics Journal

19 September 2017

published in

1 reference

19 September 2017

volume

6

1 reference

19 September 2017

issue

6

1 reference

19 September 2017

page(s)

388-396

1 reference

Dolastatin-10 in metastatic melanoma: a phase II and pharmokinetic trial of the California Cancer Consortium

19 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500386

Antitumor activity of TZT-1027, a novel dolastatin 10 derivative.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500386

TZT-1027, an antimicrotubule agent, attacks tumor vasculature and induces tumor cell death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500386

Antitumor activity of TZT-1027 (Soblidotin) against vascular endothelial growth factor-secreting human lung cancer in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500386

Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500386

Characterization of the interaction of TZT-1027, a potent antitumor agent, with tubulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500386

Induction of apoptosis in human cancer cells by TZT-1027, an antimicrotubule agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500386

Exploring the metabolic and genetic control of gene expression on a genomic scale

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500386

Integration of chemical-genetic and genetic interaction data links bioactive compounds to cellular target pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500386

Yeast genome-wide drug-induced haploinsufficiency screen to determine drug mode of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500386

Chemical genomic profiling to identify intracellular targets of a multiplex kinase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500386

Prediction of clinical drug efficacy by classification of drug-induced genomic expression profiles in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500386

Microtubules as a target for anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500386

Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500386

Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500386

Antimicrotubular drugs binding to vinca domain of tubulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500386

Rho GTPases in cell biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500386

21 January 2018

RHO-GTPases and cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500386

Identification, characterization, and crystal structure of the Omega class glutathione transferases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500386

A review of tissue inhibitor of metalloproteinases-3 (TIMP-3) and experimental analysis of its effect on primary tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500386

Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500386

A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500386

Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500386

Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate–Phenol–Chloroform Extraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500386

Identifying biological themes within lists of genes with EASE

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500386

DAVID: Database for Annotation, Visualization, and Integrated Discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500386

The isolation and structure of a remarkable marine animal antineoplastic constituent: dolastatin 10

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500386

7 January 2021

Phase II study of dolastatin-10 as first-line treatment for advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500386

7 January 2021

Phase II study of dolastatin-10 in patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500386

7 January 2021

Synthesis and antitumor activity of novel dolastatin 10 analogs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500386

7 January 2021

Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500386

7 January 2021

Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500386

7 January 2021

Association of p53 gene mutations with sensitivity to TZT-1027 in patients with clinical lung and renal carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500386

7 January 2021

Gene expression profiling of exposure to TZT-1027, a novel microtubule-interfering agent, in non-small cell lung cancer PC-14 cells and astrocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500386

7 January 2021

Identifiers

DOI

10.1038/SJ.TPJ.6500386

1 reference

19 September 2017

1 reference